Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: A1C is associated with diabetes complications but does not reflect glycemic variability (GV), which may worsen outcomes by inducing inflammation, oxidative stress, and cardiac arrhythmias. We tested whether a glucagon-like peptide 1 agonist-based regimen can reduce GV and cardiometabolic risk markers while maintaining similar A1C levels in people with insulin-requiring type 2 diabetes and high cardiovascular risk. RESEARCH DESIGN AND METHODS: After run-in on metformin and basal-bolus insulin (BBI), 102 participants continued metformin and basal insulin and were randomized to exenatide dosing before the two largest meals (glucacon-like peptide-1 receptor agonist and insulin [GLIPULIN group]) or continuation of rapid-acting insulin analogs (BBI group). Indices of GV by continuous glucose monitoring (CGM), hypoglycemia, weight, risk markers, and cardiac arrhythmias were assessed. The primary end point was change in glucose coefficients of variation (CV) by CGM from baseline to 26 weeks. RESULTS: At randomization, the median A1C was 7.3% (57 mmol/mol) for GLIPULIN and 7.4% (56.3 mmol/mol) for BBI, and glucose CVs were 30.3 for BBI and 31.9 for GLIPULIN. At 26 weeks, A1C levels were similar (7.1% [54 mmol/mol] vs. 7.2% [55 mmol/mol]), whereas mean CV improved with GLIPULIN (−2.4 vs. 0.4, P = 0.047). Other GV indices followed similar nonsignificant patterns of improvement with GLIPULIN. There were no differences in hypoglycemic events during CGM or arrhythmias during electrocardiographic monitoring. On-trial changes in body weight (−4.8 kg vs. +0.7 kg, P < 0.001), alanine aminotransferase (P = 0.0002), and serum amyloid A (P = 0.023) favored GLIPULIN. CONCLUSIONS: GLIPULIN reduced GV, weight, and some cardiometabolic risk markers while maintaining equivalent A1C levels versus BBI and might improve clinical outcomes in a larger trial.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Limited data support the possibility that GV is involved in the pathogenesis of vascular complications of diabetes by inducing inflammatory activation and oxidative stress (52,53).”
From Targets for Glycemic Control (2018) · cites this paper as [52]
In the citing paper
“Despite the improvement in GV, there was no statistically significant difference in cardiac arrhythmias”
From Glycemic variability and cardiovascular disease in patients with type 2 diabetes (2021) · cites this paper as [54]
In the citing paper
“They reported that GLP1-RA resulted in significant reductions in GV determined by CGM compared with prandial insulin.”
From Glycemic variability and cardiovascular disease in patients with type 2 diabetes (2021) · cites this paper as [54]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 2×
“26 weeks 45 3,967 (4,197) 1,625 (5,642) 43 2,583 (3,011) 1,113 (3,129) 0.”
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality
Orchard, T. J., Nathan, D. M., Zinman, B., Cleary, P., Brillon, D., Backlund, J.-Y. C., & Lachin, J. M. (2015) · JAMA · doi:10.1001/jama.2014.16107 · Cited by 437
Cited by
Items 101–139 of 139
Monnier, L., Halimi, S., & Colette, C. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30007-5 · Cited by 5
Continuous Glucose Monitoring and Glycemic Variability
Zhou, J., & Jia, W. (2018) · Springer eBooks · doi:10.1007/978-981-10-7074-7_11 · Cited by 3
La variabilité glycémique : un facteur de risque singulier à conjuguer au pluriel
Monnier, L., Colette, C., Bonnet, F., & Owens, D. R. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.11.003 · Cited by 3
O’Brien, K. D., Hirsch, I. B., Riddle, M. C., & Probstfield, J. L. (2016) · Diabetes Care · doi:10.2337/dci16-0021 · Cited by 3
Charamba, B., Liew, A., Nadeem, A., Newell, J., O'Keeffe, D. T., O’Brien, T., Wijns, W. C., Shahzad, A., & Simpkin, A. J. (2023) · PLoS ONE · doi:10.1371/journal.pone.0269968 · Cited by 3
Lim, S. K., Nishimura, R., Kesavadev, J., Kong, A. P. S., McGill, M. J., Ou, H., Chun Kwan, O., Lee, C., Zhang, X., Ji, L., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.113054 · Cited by 1
Kishan, A., Khela, H. S., Manriquez, A. H., Singh, M., Cottrill, E. J., Kazarian, G. S., Mok, J. K., Schoenfeld, A. J., Kim, H. J., Qureshi, S. A., et al. (2026) · Spine Open · doi:10.1097/bn9.0000000000000048 · Cited by 2
Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis
Liang, C.-S., Hsu, C.-C., Chen, J.-J., Hung, C.-M., Zeng, B., Yang, W.-C., Suen, M., Wang, H.-Y., Carvalho, A. F., Stubbs, B., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094137 · Cited by 2
Garg, R. (2017) · Endocrine Practice · doi:10.4158/ep-2017-0135 · Cited by 1
Continuous Glucose Monitoring and Antidiabetic Therapies
Zhou, J., & Jia, W. (2018) · Springer eBooks · doi:10.1007/978-981-10-7074-7_12 · Cited by 1
Taguchi, T., Suzuki, A., & Takano, K. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej21-0439 · Cited by 1
Bhosle, D. S., Chandekar, B., & Shelke, S. (2025) · Journal of the Association of Physicians of India · doi:10.59556/japi.73.0925 · Cited by 1
Joubert, M., & Reznik, Y. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30071-x
Diabète de type2: échec de l'insulinothérapie basale
Monnier, L., & Colette, C. (2017) · doi:10.1016/b978-2-294-74646-8.00014-6
Bonaventura, A., & Montecucco, F. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.11.004
Chapitre 15 – Diabète de type 2 : forte insulinorésistance
Monnier, L., RABASA-LHORET, R. P. R., & Colette, C. (2017)
A practical approach and algorithm for intensifying beyond basal insulin in type 2 diabetes
Goldenberg, R., Assimakopoulos, P., Gilbert, J. D., Gottesman, I. S., & Yale, J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13337
Crăciun, C.-I., Craciun, A. E., Rusu, A., Bocșan, I. C., Hâncu, N., & Buzoianu, A. D. (2018) · Revista română de medicină de laborator · doi:10.2478/rrlm-2018-0010 · Cited by 1
Newer Modalities in the Treatment of Type 2 Diabetes Mellitus: Focus on Technology
Schorr, A. B. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.84285
Drug Development for Diabetes Mellitus: Beyond Hemoglobin A1c
Bril, F., Iruarrizaga‐Lejarreta, M., & Alonso, C. (2019) · Springer eBooks · doi:10.1007/978-3-030-11748-1_15
Retnakaran, R. R., & Emery, A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13943
When and how to Use Prandial Insulin with Ultralong-Acting Basal Insulin in T2Dm
Umpierrez, G. E. (2016) · Endocrine Practice · doi:10.1016/s1530-891x(20)42964-7
When and how to Use Ultralong-Acting Basal Insulin in T2Dm
Garber, A. J. (2016) · Endocrine Practice · doi:10.1016/s1530-891x(20)42963-5
When and how to Use A Glp-1 ra With Long- or Ultralong-Acting Basal Insulin in T2Dm
Bode, B. W. (2016) · Endocrine Practice · doi:10.1016/s1530-891x(20)42965-9
Garber, A. J. (2016) · Endocrine Practice · doi:10.4158/1934-2403-22.s5.1
Manov, A., Hatharasinghe, A. T., & Lopez, K. E. (2021) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2021.10.2.0215
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Monnier, L., & Halimi, S. (2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00029-4
Modeling, Estimation, and Feedback Techniques in Type 2 Diabetes
Ahdab, M. A. (2023) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau614554303
Hajika, Y., & Kawaguchi, Y. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100377
Chen, R., Liu, W., Zhao, X., Li, N., Liu, C., Zhou, P., Chen, Y., Yan, S., Li, J., Song, L., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01967-3
Klimontov, V. V., Yakovleva, S. A., Semenova, J. F., Koroleva, E. A., Bulumbaeva, D. M., & Mavlianova, K. R. (2025) · Сибирский научный медицинский журнал · doi:10.18699/ssmj20250523
Xing, Y., Wu, M., Liu, H., Li, P., Pang, G., Zhao, H., & Wen, T. (2024) · Figshare · doi:10.6084/m9.figshare.25329765
Borkowska, A. K. C. W. I. D., Szymańska‐Garbacz, E., Kwiecińska, E., Ignaczak, A., & Czupryniak, L. K. D. I. C. W. (2017) · Via Medica Journals
Klimontov, V. V., Yakovleva, S. A., Koroleva, E. A., Bulumbaeva, D. M., Mavlianova, K. R., & Raisinezhad, K. (2025) · Diabetes Mellitus · doi:10.14341/dm13381
Yang, H., Ren, T., Zhou, J., Liu, H., yin, F., & Liu, Z. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71359
Mahmood, T., Myrtziou, I., & Kanakis, I. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02089-x
Monnier, L., Colette, C., Halimi, S., Benhamou, P., & Owens, D. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.10.013
Metadata
- Authors
- The FLAT-SUGAR Trial Investigators
- Corresponding author
- The FLAT-SUGAR Trial Investigators
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-04-19
- Volume
- 39
- Issue
- 6
- Pages
- 973-981
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2403039904
- Cited by
- 135
- References
- 21
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 4 · 2023: 5 · 2022: 5 · 2021: 17 · 2020: 11 · 2019: 20 · 2018: 23 · 2017: 20 · 2016: 13
- FWCI
- 25.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sanofi
- Bristol-Myers Squibb
- AstraZeneca
- Bayer
- Becton Dickenson
- Dexcom
- Medicomp
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- glycemic variability, type 2 diabetes, GLP-1 receptor agonists, exenatide, rapid-acting insulin analogs, multiple daily insulin injections, cardiovascular risk, glycemic control, HbA1c, hypoglycemia, cardiac arrhythmias, body weight, cardiometabolic risk markers, serum amyloid A, alanine aminotransferase
- MeSH terms
- Exenatide, Adult, Aged, Alanine Transaminase, Serum Amyloid A Protein, Arrhythmias, Cardiac, Blood Glucose, Body Weight, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Risk Factors, Venoms, Insulin, Short-Acting, Meals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.